Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29910996 | 1.00 | TTR (0.46) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL20153700 | 0.90 | KDM4E (0.47) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL21002191 | 0.81 | TRPV1 (0.41) | CNR2NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL21002167 | 0.81 | TRPV1 (0.41) | CNR2NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL21002094 | 0.81 | KDM4E (0.59) | NPC1RAB9AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL21002093 | 0.81 | KDM4E (0.59) | NPC1RAB9AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL20153736 | 0.81 | TTR (0.42) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL12499737 | 0.80 | KDM4E (0.62) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL11014364 | 0.80 | KDM4E (0.62) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL13320457 | 0.79 | TTR (0.41) | TTRDPP4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2021-07-01 | — | — | US | disclosed |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2019103897-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | AURANSA INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2018089357-A1 | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | TTR 531/4885DPP4 2947/4885CA12 4227/4885 |
| US-20200377510-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | SHARPIN, PIR, THPO | TTR 1887/4885DPP4 332/4885CA12 4188/4885 |
| US-20190256496-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | TTR 531/4885DPP4 2947/4885CA12 4227/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | TTR 661/4885DPP4 2679/4885CA12 3696/4885 |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | ITGAV, ITGB1, ITGB3 | TTR 531/4885DPP4 2947/4885CA12 4227/4885 |
| US-20210198235-A1 | DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF | THPO, PIR, PAK6 | TTR 3340/4885DPP4 559/4885CA12 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.